Andrew Wills Stephens
Physician at Kelly Rd, Boulder, CO

License number

Colorado 32059

Issued Date

Aug 21, 1992

Renew Date

Jun 1, 2003

Expiration Date

May 31, 2005

Type

Physician

Address

740 Kelly Rd W, Boulder, CO 80302

Professional information

Bioconjugation Of Macromolecules

US Patent:

6737236, May 18, 2004

Filed:

Jul 8, 1999

Appl. No.:

09/341337

Inventors:

Wolfgang Pieken - Boulder CO
Ken Hill - Nederland CO
Bruce Eaton - Boulder CO
Danny McGee - San Mateo CA
Kurt Vagle - Longmont CO
Larry Gold - Boulder CO
Andrew Stephens - Boulder CO

Assignee:

Proligo, LLC - Boulder CO

International Classification:

C12Q 168

US Classification:

435 6, 435174, 568767, 4241931, 534766, 536 221, 530350

Abstract:

This invention discloses a novel method for conjugating macromolecules to other molecular entities. Specifically, this invention discloses a method for conjugating or derivatizing macromolecules, such as oligonucleotides and proteins, using cycloaddition reactions, such as the Diels-Alder reaction or 1,3-dipolar cycloadditions. Included in the invention are the novel bioconjugated macromolecules that can be prepared according to the method of the invention.

Compounds As Aptamer-Dimers And Their Uses In Diagnosis And Therapy

US Patent:

2008020, Aug 28, 2008

Filed:

Sep 7, 2007

Appl. No.:

11/851789

Inventors:

Matthias Friebe - Berlin, DE
Andrew Stephens - Boulder CO, US
Ananth Srinivasan - Berlin, DE
Maren Hecht - Berlin, DE

International Classification:

A61K 38/08, C07K 7/06, A61P 35/00, C07K 1/00

US Classification:

514 15, 530329, 530328, 530327, 530333, 514 16

Abstract:

The object of the present invention is solved by compositions of peptide linkers and their use for synthesis and annealing of aptamer oligonucleotides in form of dimers. The present invention in particularly provides said compositions for the use as a diagnostic and/or therapeutic agent.In another preferred embodiment the present invention relates to a kit for preparing a radiopharmaceutical preparation, said kit comprising a vial comprising a quantity of the compound according to the invention.A further preferred embodiment of the present invention relates to methods of producing said compounds, comprising synthesis of said compound in an automated peptide synthesizer.In another preferred embodiment the present invention concerns the use of said compounds according to the present invention for the manufacture of a medicament, preferably for diagnosis or therapy of proliferative diseases.In a further preferred embodiment the present invention concerns methods for treating or diagnosing patients administering or utilizing the compounds according to the present invention.

Nucleic Acid Ligands Of Tissue Target

US Patent:

6127119, Oct 3, 2000

Filed:

Nov 21, 1997

Appl. No.:

8/976413

Inventors:

Andrew Stephens - Boulder CO
Larry Gold - Boulder CO
Ulrich Speck - Berlin, DE

Assignee:

NeXstar Pharmaceuticals, Inc. - Boulder CO

International Classification:

C12Q 168, C12P 1934, C07H 2102, C07H 2104

US Classification:

435 6

Abstract:

This invention discloses high-affinity oligonucleotide ligands to complex tissue targets, specifically nucleic acid ligands having the ability to bind to complex tissue targets, and the methods for obtaining such ligands. Tissue targets comprise cells, subcellular components, aggregates or cells, collections of cells, and higher ordered structures. Specifically, nucleic acid ligands to blood vessels are described.

Systematic Evolution Of Ligands By Exponential Enrichment: Tissue Selex

US Patent:

6114120, Sep 5, 2000

Filed:

Oct 28, 1997

Appl. No.:

8/945909

Inventors:

Kirk B Jensen - New York NY
Hang Chen - San Francisco CA
Kevin N. Morris - Goldegg, AT
Andrew Stephens - Boulder CO
Larry Gold - Boulder CO

Assignee:

NeXstar Pharmaceuticals, Inc. - Boulder CO

International Classification:

C07H 2102, C07H 2104, C12P 1934, C12Q 168

US Classification:

435 6

Abstract:

A new class of nucleic acid compounds, referred to as nucleic acid ligands, have been shown to exist that have a specific binding affinity for three dimensional molecular targets, including cell surface macromolecules. The nucleic acid ligands are identified by the method of the invention referred to as the Systematic Evolution of Ligands by EXponential enrichment (SELEX), wherein a candidate mixture of nucleic acids are iteratively enriched and the high affinity nucleic acids are amplified for further partitioning. The high affinity nucleic acid ligands are useful in capturing target cells.

Nucleic Acid Ligands To Integrins

US Patent:

6331394, Dec 18, 2001

Filed:

Jul 29, 1999

Appl. No.:

9/364543

Inventors:

Judy Ruckman - Boulder CO
Larry Gold - Boulder CO
Andrew Stephens - Boulder CO
Nebojsa Janjic - Boulder CO

Assignee:

Gilead Sciences, Inc. - Foster City CA

International Classification:

C12Q 168, C12P 1934, C07H 2102, C07H 2104

US Classification:

435 6

Abstract:

Methods are described for the isolation of nucleic acid ligands to integrins using the SELEX process. SELEX is an acronym for Systematic Evolution of Ligands by EXponential enrichment. The nucleic acid ligands of the present invention are useful as therapeutic and diagnostic agents.